Condition: Pulmonary Hypertension · Interstitial Lung Disease (ILD) · Lung Diseases · Sponsor: Pulmovant, Inc.
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
This description comes directly from the study's public registry record.
Pulmovant · +1-919-462-1310 · clinicaltrials@pulmovant.com
Always discuss trial participation with your own doctor first.
| Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC | Kissimmee, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07333183